Alexion Receives FDA Approval for New Advanced Formulation of Ultomiris (ravulizumab-cwvz) with Significantly Reduced Infusion Time

BOSTON--(BUSINESS WIRE)--Oct. 12, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) 100 mg/mL formulation for the treatment of adults with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news